Cost per responder of adalimumab biosimilars versus methotrexate in patients with psoriasis: a real-life experience

Figures & data

Table 1. Characteristics of study population (patients treated with adalimumab and methotrexate).

	Amgevita	Idacio	Methotrexate
Number	160	250	302
Age	52.4 (12.6)	51.8 (14.5)	59.1 (10.4)
Male gender	96 (60%)	155 (62%)	193 (64%)
PASI	15.12 ± 4.9	14.54 ± 5.02	10.11 ± 3.8
BMI	26.72 ± 3.21	26.81 ± 4.11	27.12 ± 2.35
PsA	30.4 (19%)	45 (18%)	48.3 (16%)
Type 2 diabetes	12.9 (8.1)	19.5 (7.8)	26.8 (8.9)

PASI: psoriasis area severity index; BMI: body mass index; PsA: psoriatic arthritis.

Table 2. Drug costs of adalimumab biosimilars, methotrexate and folic acid according to list price (in Euro).

Drug	Ex-factory price per package	Discount *	Discounted price per package
Amgevita^® 40 mg, 2 syringes	854.84	82.31%	83.16
Idacio^® 40 mg, 2 syringes	758.68	88.69%	47.19
Methotrexate 12.5 mg, 4 syringes	34.14	N.A.	N.A.
Folic acid 5 mg, 120 tablets	12.45	N.A.	N.A.

*Discounted prices were derived from: http://azero.veneto.it/public/alboOnline.xhtml?pageType=all.

https://www.gazzettaufficiale.it/eli/id/2016/11/11/16A07913/sg https://www.gazzettaufficiale.it/eli/id/2021/07/28/21A04520/SG#:∼:text=Prezzo%20al%20pubblico%20(iva%20inclusa,E%20(in%20base%2010).

N.A. not applicable.

Table 3. Retention rate at week 24 and 52 in the study population (patients treated with adalimumab and methotrexate).

Drug	Retention rate at week 24	CI 95%	Retention rate at week 52	CI 95%
Amgevita® 40 mg, 2 syringes	86%	79–91	81%	74–86
Idacio® 40 mg, 2 syringes	90%	86–94	82%	76–84
Methotrexate 12.5 mg, 4 syringes	78%	72–85	63%	58–76

Figure 1. Cost per responder analysis for patients receiving ABP 501 (Amgevita®) (black histogram), MSB11022 (Idacio®) (grey histogram) and methotrexate (white histogram) at week 24.

Figure 2. Cost per responder analysis for patients receiving ABP 501 (Amgevita®) (black histogram), MSB11022 (Idacio®) (grey histogram) and methotrexate (white histograms) at week 52.

Table 4. Cost per responder of adalimumab biosimilars and methotrexate at week 24 and 52 (in Euro).

Drug	Ex-factory price	Discounted price	Ex-factory price	Discounted price
	Week 24		Week 52
Amgevita® 40 mg, 2 syringes	6941.30	674.73	14720.30	1430.94
Idacio® 40 mg, 2 syringes	5894.94	366.66	12852.00	799.26
Methotrexate 12.5 mg, 4 syringes	264.59	264.59	652.09	652.09

Data availability statement

The authors confirm that the data supporting the findings of this study are available within the article and its supplementary materials.